Real-World Treatment Study of Koselugo (Selumetinib)
← catalyst calendarNCT06360406 · readout in 1,867 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
12
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-15 | actual | When the study began enrolling |
| Primary completion | 2031-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neurofibromatosis 1
- Neurofibroma, Plexiform
Primary outcomes
what the primary-completion date above is the date OFAdverse events (AEs) rate
measured 1 year
Physeal dysplasia occurance rate
measured 1 year
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed